LaDuane Clifton, Zevra’s Chief Financial Officer said, “This non-dilutive capital strengthens our balance sheet by adding gross cash proceeds of $150 million, supporting continued investment in our ...

Zevra Therapeutics has inked a deal to sell its Food and Drug Administration priority-review voucher to an undisclosed buyer for gross proceeds of $150 million.

Zevra Therapeutics (ZVRA) has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ...

For Zevra Therapeutics, last year’s approval of the rare lysosomal storage disorder drug Miplyffa appears to be the gift that ...

Investing.com -- Shares of Zevra Therapeutics, Inc. ( Nasdaq: ZVRA) climbed 8% following the announcement that the company has entered into an agreement to sell its Rare Pediatric Disease Priority ...

Rare disease-focused biopharma Zevra Therapeutics has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to an undisclosed buyer for $150 million.

Zevra has sold its US Food and Drug Administration (FDA) priority review voucher (PRV) for $150m to an undisclosed party.

IntraBio's Aqneursa (levacetylleucine) has joined Zevra Therapeutics' Miplyffa (arimoclomol) for patients with Niemann-Pick type C (NPC), a rare genetic disease affecting around one in 100,000 ...